Summary: These are the guidelines on hepatitis B and C management for IUSTI/WHO in Europe, 2010. They describe the epidemiology, diagnosis, clinical features, treatment and prevention of hepatitis B and C with particular reference to sexual health clinical practice.
HEPATITIS B VIRUS INFECTION

Introduction
Hepatitis B is caused by an hepadna (DNA) virus. Despite the availability of a vaccine, hepatitis B virus (HBV) infection is endemic, estimated to affect 400 million people worldwide, with very high hepatitis B surface antigen (HBsAg) carriage rates (up to 20%) particularly in south and east Asia. High carriage rates (up to 10%) are also found in some regions of Central and South America, Africa and parts of Asia. The reported incidence of acute hepatitis B in 2004 was 0-10/ 100,000 population in most of Europe but was 10-50/100,000 in Albania and most of eastern Europe. 1, 2 There has been a steady decline in incidence, particularly in western Europe, in the last two decades. Chronic carriage in the general population occurs in .8% in parts of eastern Europe, 2-8% in southern Europe and 0.1-2% in northern and western Europe. 3 However, much higher carriage rates are found in certain subgroups including injecting drug users (IDUs), men who have sex with men (MSM), female sex workers and immigrants from high endemicity countries. 4 -7 Transmission † Sexual transmission occurs in unvaccinated MSM and correlates with multiple partners and unprotected anal sex. 5,6,8 -11 Transmission also occurs after heterosexual contact (e.g. 18% infection rates for regular partners of patients with acute hepatitis B). 12 -14 Sex workers are also at higher risk.
7,15 † Other routes are parenteral (blood, blood products, drug-users sharing needles and syringes, needle-stick exposures), vertical (infected mother to infant) 9,13,16 -18 and oro-anal sex 5,6,8 -11 † Sporadic infection occurs in people without apparent risk factors, in institutions for the mentally disabled and also in children in countries of high endemicity. 19, 20 Overall, HBV is much more transmissible than HIV.
Diagnosis
Clinical Acute icteric hepatitis has an incubation period of 40-160 days. Virtually all infants and children, and 10 -50% of adults (especially HIV positive) have asymptomatic acute infection. 21 -24 In chronic infection there are often no symptoms or physical signs. After many years of infection, there may be signs of chronic liver disease. 10,24 -27 There are four phases of chronic carriage:
(1) Immune tolerant (hepatitis B e antigen [HBeAg] positive, normal aminotransferase levels, high serum HBV DNA, little or no necro-inflammation on liver biopsy); (2) Immune active, eAg-positive phase (HBeAg positive, raised aminotransferases, high serum HBV DNA, progressive necro-inflammation and fibrosis); (3) Inactive hepatitis B carrier (HBsAg positive, HBeAg negative, low levels of HBV DNA and normal aminotransferases); (4) eAg negative chronic active hepatitis (Pre-core or corepromoter mutations, HBeAg negative, intermediate serum HBV DNA levels, progressive inflammation and fibrosis) -reactivation.
Types 2 and 4 may progress to cirrhosis and liver cancer, with type 4 generally progressing fastest. 25, 26 Between 15% and 40% of patients with chronic infection will develop serious complications. † Chronic HBV infection -in most cases the only abnormality to be found will be mildly abnormal aminotransferase levels (usually ,100 IU/L) and in many patients the liver function tests (LFT) will be normal, particularly in the immune tolerant and inactive carrier stages. 10,23 -27 Indications for HBV testing (1) 
Screening tests in asymptomatic patients
Initial screening for hepatitis B can be achieved by using either the antihepatitis B core antibody (anti-HBc) or HBsAg tests or both, followed by further tests accordingly (see flow charts and table for interpretation). Anti-HBc as the first test has the advantage that it will detect evidence of current or past infection allowing decisions to be made about the need for vaccination or treatment. 28 -33 However false-positive test results may occur and people who are anti-HBc positive, anti-HBs negative may be considered as possibly non-immune (see below). An alternative screening strategy is to test for HBsAg initially which detects active infection but does not allow vaccination decisions to be made unless the anti-HBc test is also used [IIa, B] (see Figures 1 and 2) .
If, after screening, the patient is found to be non-immune, consider vaccination (see below) 16 10,23 -26 [IV, C]. Among others, assessment of liver synthetic function (albumin, prothrombin time), disclosure of portal hypertension ( platelets, ultrasonography) and liver fibrosis estimation using non-invasive markers (serum fibrosis indexes or imaging techniques such as elastometry) are warranted. Liver biopsy may be considered in patients in whom other hepatic diseases want to be excluded or when required by treatment protocols. Otherwise, liver biopsy is no longer mandatory as part of regular chronic hepatitis B assessment. † All HBsAg-positive patients, but especially those with cirrhosis of high HBV-DNA levels, are at risk for hepatocellular carcinoma and should be followed by a specialist in liver disease.
Management of HBsAg-positive patients
Indications for therapy
Chronic infection † Treatment should normally be given in collaboration with a hepatologist or physician experienced in the management of chronic viral hepatitis [IV, C]. The decision to treat depends on pattern of disease, HBV-DNA level, and presence or absence of significant necro-inflammation and hepatic fibrosis. HBV-DNA thresholds of 2 Â 10 4 , 2 Â 10 3 and 2 Â 10 3 IU/mL are often used for HBeAg-positive chronic hepatitis, HBeAg -ve chronic hepatitis and cirrhosis, respectively, for initiating therapy. 26 Acute infection A small minority of patients with very severe acute infection may benefit from treatment with lamivudine, entecavir or telbivudine. 62 Such patients should be referred to a liver specialist [III, C]. Management of partners and other contacts † Partner notification should be performed and documented and the outcome documented at subsequent follow up. Contact tracing to include any sexual contact ( penetrative vaginal or anal sex or oro-anal sex) or needle sharing partners during the period in which the index case is thought to have been infectious 29, 30, 31, 74 [IIa, A] . The infectious period is from two weeks before the onset of jaundice until the patient becomes HBsAg negative. In cases of chronic infection trace contacts as far back as any episode of jaundice or to the time when the infection is thought to have been acquired although this may be impractical for periods of longer than two or three years [IV, C]. Arrange screening for hepatitis B in children who have been born to infectious women if the child was not vaccinated at birth 16 
Special situations
Hepatitis D (delta virus infection, HDV)
This is an incomplete RNA virus that requires the hepatitis B virus outer coat. It is only found in patients with hepatitis B. It is largely an infection of IDUs and their sexual partners, but also in female sex-workers, and sporadically in other groups. 76 Suspect HDV in hepatitis B, particularly if the acute hepatitis is severe, if chronic hepatitis B carriers get a further attack of acute hepatitis or if the liver disease in chronic HBV is rapidly progressive 10 
HEPATITIS C VIRUS INFECTION
Introduction
A RNA virus in the flaviviridae family. It is endemic worldwide with high prevalence rates (.10%) in Mongolia, Egypt, Cameroon, Guinea and Bolivia. 4, 78 The WHO estimates that 3% of the world's population is infected, with four million carriers in Europe. The prevalence in most European countries is 1-2.5% with the highest rates in Moldova and Romania (2.5 -10%). 79 Within most countries the highest rates are in IDUs and men with haemophilia. 4, 79 Transmission † Parenteral spread accounts for the majority of cases through shared needles/syringes and other drug paraphernalia (e.g. filters, water) in IDUs, transfusion of contaminated blood or blood products ( pre 1990s), renal dialysis, sharing razors with infected individuals or needle-stick injury.
79 -85 † Sexual transmission occurs at a low rate (approximately 0.2-2% per year of relationship), but this rate increases if the index patient and/or the recipient or both are HIV-infected. 86 -92 There has been a steady rise in acute HCV throughout Europe in MSM over the last 10 years, mostly associated with HIV-co-infection. 11, 87, 88, 90 Other factors linked to HCV in MSM include ulcerative STIs such as syphilis and lymphogranuloma venereum, traumatic anal sexual practices and recreational drugs such as cocaine snorting. 11, 87, 88, 90 There is also evidence of slightly increased risk of HCV infection in female sex workers, former prisoners, tattoo recipients and alcoholics.
7,93 -96 † Vertical (mother to infant) spread also occurs at a low rate (5% or less) in HCV-RNA-positive women. 86,97 -101 Higher rates (usually around 20% but up to 40%) are seen if the woman is both HIV and HCV positive, most likely associated with high serum HCV-RNA levels in these carriers. When considering a clinical diagnosis of hepatitis C, there are no features that distinguish it reliably from HBV or HAV. The clinical pointers to hepatitis C would be whether there was a history of travel, parenteral and sexual exposures and the incubation period.
The majority of patients (.80%) undergo asymptomatic acute infection. 81 ,82,103 † More than twenty percent have acute icteric hepatitis 81, 82, 103 but fulminant hepatitis is particularly common after hepatitis A super-infection of chronic hepatitis C carriers. 104 † Approximately 70 -85% of individuals with acute hepatitis C become chronic carriers -a state which is generally asymptomatic but may cause non-specific ill health. 103, 105, 106 Some reports suggest that HCV genotype 1 could clear spontaneously more often, but leads to more severe liver disease. 105 Once established, the rate of progression of the liver disease varies from patient to patient (0.02%/ year). 81, 82 Liver cirrhosis and decompensated liver disease appears earlier if there is a high alcohol intake or other liver disease, including steatohepatitis. 107 -110 Significant liver disease can be present in up to 35% of carriers who have normal serum aminotransferase levels. 81, 82, 111, 112 Laboratory † A screening antibody test such as an enzyme immunoassay (EIA) or other immunoassay is initially performed and RT-PCR for RNA is used to confirm active infection [IIa, B] . 114 -117 In HIV-positive patients with a low CD4 count (,200 cells/mm 3 ) the EIA may occasionally be negative and an RT-PCR may be needed for definitive diagnosis [IIb, B] . 113 An antibody test may not become positive for three or more months after acute HCV infection but a test for HCV-RNA will be positive after only two weeks [IIb, B] . 114 -117 Chronic infection is confirmed if an HCV-RNA assay is positive six months after the first positive test. Patients with low-level viraemia may require HCV-RNA levels testing on two or more occasions to confirm infection [IIb, B]. 114 -117 All patients being considered for therapy should have a viral RNA test to confirm viraemia and be genotyped. A positive antibody test with persistently negative RNA tests indicates resolved infection [IIb, B].
114 -117 † Acute HCV infection -ALT levels are raised but rarely .1000 IU/L; serum bilirubin: rarely .300 mmol/L; alkaline phosphatase is generally ,2Â the upper limit of normal, except in cases complicated by cholestasis. Prothrombin time is rarely prolonged by up to five seconds; greater prolongation indicates developing hepatic failure. † Chronic HCV infection -in most cases the only abnormality to be found will be mildly abnormal aminotransferase levels (usually ,100 IU/L) and in a third of patients the LFTs will be normal (defined as 19 IU/L for women and ,30 IU/L in men).
Indications for HCV testing . 80 -84 (ii) Other groups to be considered for testing are sexual partners of HCV-positive individuals, MSM, especially if HIV-infected, female sex workers, tattoo recipients, alcoholics and ex-prisoners [III, B]. 7,11,87,88,90,93 -96 It may take three months or more for the anti-HCV test to become positive after exposure (see 'diagnosis'). (3) All HIV-infected persons, especially from the countries where the HIV epidemic has been driven by IDUs and especially prior to HAART. 81, 123, 124 Among others, assessment of liver synthetic function (albumin, prothrombin time), disclosure of portal hypertension ( platelets, ultrasonography) and liver fibrosis estimation using noninvasive markers (serum fibrosis indexes or imaging techniques such as elastometry) are warranted. Liver biopsy may be considered in patients in whom other hepatic diseases want to be excluded or when required by treatment protocols. Otherwise, liver biopsy is no longer mandatory as part of regular chronic hepatitis C assessment. † All patients with cirrhosis should be screened for hepatocellular carcinoma, ideally every six months, by a specialist in liver disease.
Indications for therapy † Acute icteric hepatitis: There is firm evidence that pegylated interferon (with or without ribavirin) given during the acute phase will reduce the rate of chronicity to only 10% or less [Ia, A] 125 -127 Spontaneous resolution of acute hepatitis C is presumed when there is a loss of HCV-RNA within the first 12 weeks, although fluctuations are not rare during the first year following acute HCV exposure. Only those HCV-RNA positive for more than 12 weeks need to be treated. 126 HCV genotype 1 and 4 infections require 24 weeks' therapy whereas HCV genotypes 2 or 3 need only 12 weeks' treatment 126 [Ia, A] . If HIV positive, the patient may need to be treated earlier than 12 weeks and should see a specialist in this area of management. † Chronic HCV infection: Pegylated interferon alfa with ribavirin will cure chronic infection in approximately 50% of patients [Ia, A]. 128 -133 However, the treatment required will vary according to the genotype, initial treatment response and other factors. Treatment should be for 12 -24 weeks for patients with genotypes 2 or 3, 131, 133 although HCV genotype 3 patients with advanced liver fibrosis and detectable HCV-RNA at week 4 of therapy may benefit from longer treatment duration (12 months). All other HCV genotypes (including 1 and 4) should be treated for 12 -18 months. Treatment should be discontinued if there has not been a reduction in HCV viral load .2 log at week 12 of therapy or undetectable levels at week 24. Patients achieving undetectable viral load at week 4 (rapid virological responders) have the greatest chances of cure and may benefit from shorter courses of therapy 132 . Patients are more likely to respond if they do not have cirrhosis, have low serum HCV-RNA levels (,500,000 IU/mL), if they are infected with certain HCV genotypes (types 2 and 3) [ Management of partners and other contacts † Partner notification should be performed and the outcome documented at subsequent follow-up [IV, C]. Contact tracing to include needle sharing partners and any sexual contact ( penetrative vaginal or anal sex) or during the period in which the index case is thought to have been infectious. 11,79,80,86 -92 The infectious period is from four weeks before the onset of jaundice in acute infection. If there was no acute infection, trace back to the likely time of infection (e.g. blood transfusion, first needle sharing) although this may be impractical for periods longer than two or three years [IV, C] . Consider testing children born to infectious women [III, B] . 87,98 -102 For other non-sexual contacts thought to be at risk, discuss with the public health physician. † There is currently no available vaccine or immunoglobulin preparation that will prevent HCV acquisition. † Sexual transmission should be discussed. It seems likely that if condoms are used consistently then sexual transmission will be avoided [ 
